US 11,752,157 B2
Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
Joan-Carles Arce, Dragor (DK)
Assigned to Ferring B.V., Hoofddorp (NL)
Filed by Ferring B.V., Hoofddorp (NL)
Filed on May 18, 2020, as Appl. No. 16/877,186.
Application 16/877,186 is a continuation of application No. 15/538,639, granted, now 10,688,106, previously published as PCT/NL2015/050893, filed on Dec. 21, 2015.
Application 15/538,639 is a continuation of application No. 14/643,307, filed on Mar. 10, 2015, granted, now 9,579,305, issued on Feb. 28, 2017.
Claims priority of application No. 14199709 (EP), filed on Dec. 22, 2014.
Prior Publication US 2020/0352962 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/404 (2006.01); A61B 17/435 (2006.01); A61K 31/57 (2006.01); A61K 38/095 (2019.01); A61K 38/12 (2006.01); A61K 45/06 (2006.01); A61K 31/4045 (2006.01); A61K 31/565 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/57 (2013.01) [A61B 17/435 (2013.01); A61K 9/0019 (2013.01); A61K 9/0034 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/565 (2013.01); A61K 38/095 (2019.01); A61K 38/12 (2013.01); A61K 45/06 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method for treating a female subject undergoing embryo transfer comprising administering to the female subject an oxytocin receptor antagonist formulated as a sustained or delayed release formulation, such that an effect of the antagonist overlaps with a receptive endometrium stage in said female subject and transferring a blastocyst-stage embryo into a uterus, a uterine cavity, or fallopian tubes of the female subject.